US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines

Mona Saraiya; Elizabeth R Unger; Trevor D Thompson; Charles F Lynch; Brenda Y Hernandez; Christopher W Lyu; Martin Steinau; Meg Watson; Edward J Wilkinson; Claudia Hopenhayn; Glenn Copeland; Wendy Cozen; Edward S Peters; Youjie Huang; Maria Sibug Saber; Sean Altekruse; Marc T Goodman; HPV Typing of Cancers Workgroup

doi:10.1093/jnci/djv086

Back

US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines

Journal article

Open access

Peer reviewed

US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines

Mona Saraiya, Elizabeth R Unger, Trevor D Thompson, Charles F Lynch, Brenda Y Hernandez, Christopher W Lyu, Martin Steinau, Meg Watson, Edward J Wilkinson, Claudia Hopenhayn, …

JNCI : Journal of the National Cancer Institute, Vol.107(6), pp.djv086-djv086

06/2015

DOI: 10.1093/jnci/djv086

PMCID: PMC4838063

PMID: 25925419

Files and links (1)

url

https://doi.org/10.1093/jnci/djv086View

Published (Version of record) Open Access

Abstract

This study sought to determine the prevaccine type-specific prevalence of human papillomavirus (HPV)-associated cancers in the United States to evaluate the potential impact of the HPV types in the current and newly approved 9-valent HPV vaccines. The Centers for Disease Control and Prevention partnered with seven US population-based cancer registries to obtain archival tissue for cancers diagnosed from 1993 to 2005. HPV testing was performed on 2670 case patients that were fairly representative of all participating cancer registry cases by age and sex. Demographic and clinical data were evaluated by anatomic site and HPV status. Current US cancer registry data and the detection of HPV types were used to estimate the number of cancers potentially preventable through vaccination. HPV DNA was detected in 90.6% of cervical, 91.1% of anal, 75.0% of vaginal, 70.1% of oropharyngeal, 68.8% of vulvar, 63.3% of penile, 32.0% of oral cavity, and 20.9% of laryngeal cancers, as well as in 98.8% of cervical cancer in situ (CCIS). A vaccine targeting HPV 16/18 potentially prevents the majority of invasive cervical (66.2%), anal (79.4%), oropharyngeal (60.2%), and vaginal (55.1%) cancers, as well as many penile (47.9%), vulvar (48.6%) cancers: 24 858 cases annually. The 9-valent vaccine also targeting HPV 31/33/45/52/58 may prevent an additional 4.2% to 18.3% of cancers: 3944 cases annually. For most cancers, younger age at diagnosis was associated with higher HPV 16/18 prevalence. With the exception of oropharyngeal cancers and CCIS, HPV 16/18 prevalence was similar across racial/ethnic groups. In the United States, current vaccines will reduce most HPV-associated cancers; a smaller additional reduction would be contributed by the new 9-valent vaccine.

Registries

Adult

Aged

Alphapapillomavirus - genetics

Alphapapillomavirus - isolation & purification

DNA, Viral - isolation & purification

Female

Human papillomavirus 16 - isolation & purification

Human papillomavirus 18 - isolation & purification

Humans

Laryngeal Neoplasms - prevention & control

Laryngeal Neoplasms - virology

Male

Middle Aged

Neoplasms - prevention & control

Neoplasms - virology

Oropharyngeal Neoplasms - prevention & control

Oropharyngeal Neoplasms - virology

Papillomavirus Infections - complications

Papillomavirus Infections - prevention & control

Papillomavirus Infections - virology

Papillomavirus Vaccines - administration & dosage

Papillomavirus Vaccines - immunology

Penile Neoplasms - prevention & control

Penile Neoplasms - virology

United States - epidemiology

Uterine Cervical Neoplasms - prevention & control

Uterine Cervical Neoplasms - virology

Vulvar Neoplasms - prevention & control

Vulvar Neoplasms - virology

Details

Title: Subtitle: US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines
Creators: Mona Saraiya - National Center for Chronic Disease Prevention and Health Promotion
Elizabeth R Unger - Centers for Disease Control and Prevention
Trevor D Thompson - Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion (MSa, TDT, MW) and Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases (ERU, MSt), Centers for Disease Control and Prevention, Atlanta, GA; University of Hawaii Cancer Center, University of Hawaii, Honolulu, HI (MTG, BYH); Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA (CFL); Departments of Preventive Medicine (WC) and Pathology (WC, MSS), University of Southern California, Los Angeles, CA; Department of Epidemiology, School of Public Health, Louisiana State University Health Sciences Center, New Orleans, LA (ESP); Department of Pathology, Immunology, and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL (EJW); Michigan Department of Community Health, Lansing, MI (GC); Department of Epidemiology, College of Public Health, University of Kentucky, Lexington, KY (CH); Florida Department of Health, Tallahassee, FL (YH); Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD (SFA); Battelle Memorial Institute, Durham, NC (CWL); National Cancer Institute (SA)
Charles F Lynch - University of Iowa, Epidemiology
Brenda Y Hernandez - University of Hawaii System
Christopher W Lyu - Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion (MSa, TDT, MW) and Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases (ERU, MSt), Centers for Disease Control and Prevention, Atlanta, GA; University of Hawaii Cancer Center, University of Hawaii, Honolulu, HI (MTG, BYH); Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA (CFL); Departments of Preventive Medicine (WC) and Pathology (WC, MSS), University of Southern California, Los Angeles, CA; Department of Epidemiology, School of Public Health, Louisiana State University Health Sciences Center, New Orleans, LA (ESP); Department of Pathology, Immunology, and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL (EJW); Michigan Department of Community Health, Lansing, MI (GC); Department of Epidemiology, College of Public Health, University of Kentucky, Lexington, KY (CH); Florida Department of Health, Tallahassee, FL (YH); Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD (SFA); Battelle Memorial Institute, Durham, NC (CWL); National Cancer Institute (SA)
Martin Steinau - Centers for Disease Control and Prevention
Meg Watson - National Center for Chronic Disease Prevention and Health Promotion
Edward J Wilkinson - University of Florida
Claudia Hopenhayn - University of Kentucky
Glenn Copeland - Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion (MSa, TDT, MW) and Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases (ERU, MSt), Centers for Disease Control and Prevention, Atlanta, GA; University of Hawaii Cancer Center, University of Hawaii, Honolulu, HI (MTG, BYH); Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA (CFL); Departments of Preventive Medicine (WC) and Pathology (WC, MSS), University of Southern California, Los Angeles, CA; Department of Epidemiology, School of Public Health, Louisiana State University Health Sciences Center, New Orleans, LA (ESP); Department of Pathology, Immunology, and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL (EJW); Michigan Department of Community Health, Lansing, MI (GC); Department of Epidemiology, College of Public Health, University of Kentucky, Lexington, KY (CH); Florida Department of Health, Tallahassee, FL (YH); Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD (SFA); Battelle Memorial Institute, Durham, NC (CWL); National Cancer Institute (SA)
Wendy Cozen - University of Southern California
Edward S Peters - Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion (MSa, TDT, MW) and Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases (ERU, MSt), Centers for Disease Control and Prevention, Atlanta, GA; University of Hawaii Cancer Center, University of Hawaii, Honolulu, HI (MTG, BYH); Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA (CFL); Departments of Preventive Medicine (WC) and Pathology (WC, MSS), University of Southern California, Los Angeles, CA; Department of Epidemiology, School of Public Health, Louisiana State University Health Sciences Center, New Orleans, LA (ESP); Department of Pathology, Immunology, and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL (EJW); Michigan Department of Community Health, Lansing, MI (GC); Department of Epidemiology, College of Public Health, University of Kentucky, Lexington, KY (CH); Florida Department of Health, Tallahassee, FL (YH); Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD (SFA); Battelle Memorial Institute, Durham, NC (CWL); National Cancer Institute (SA)
Youjie Huang - Florida Department of Health
Maria Sibug Saber - Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion (MSa, TDT, MW) and Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases (ERU, MSt), Centers for Disease Control and Prevention, Atlanta, GA; University of Hawaii Cancer Center, University of Hawaii, Honolulu, HI (MTG, BYH); Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA (CFL); Departments of Preventive Medicine (WC) and Pathology (WC, MSS), University of Southern California, Los Angeles, CA; Department of Epidemiology, School of Public Health, Louisiana State University Health Sciences Center, New Orleans, LA (ESP); Department of Pathology, Immunology, and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL (EJW); Michigan Department of Community Health, Lansing, MI (GC); Department of Epidemiology, College of Public Health, University of Kentucky, Lexington, KY (CH); Florida Department of Health, Tallahassee, FL (YH); Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD (SFA); Battelle Memorial Institute, Durham, NC (CWL); National Cancer Institute (SA)
Sean Altekruse - National Cancer Institute
Marc T Goodman - Cedars-Sinai Medical Center
HPV Typing of Cancers Workgroup
Resource Type: Journal article
Publication Details: JNCI : Journal of the National Cancer Institute, Vol.107(6), pp.djv086-djv086
DOI: 10.1093/jnci/djv086
PMID: 25925419
PMCID: PMC4838063
NLM abbreviation: J Natl Cancer Inst
ISSN: 0027-8874
eISSN: 1460-2105
Publisher: Oxford University Press
Grant note: N01-PC-35139 / NCI NIH HHS 1U58DP000807-3 / NCCDPHP CDC HHS N01-PC-2010-00035 / NCI NIH HHS P30 CA086862 / NCI NIH HHS N01-PC-35137 / NCI NIH HHS N01-PC-35143 / NCI NIH HHS
Language: English
Date published: 06/2015
Academic Unit: Epidemiology
Record Identifier: 9983996193402771

Metrics

82 Record Views

624 Times Cited - Web of Science